Gencurix Inc
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more
Gencurix Inc - Asset Resilience Ratio
Gencurix Inc (229000) has an Asset Resilience Ratio of 4.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Gencurix Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Gencurix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.08 Billion | 4.01% |
| Total Liquid Assets | ₩1.08 Billion | 4.01% |
Asset Resilience Insights
- Limited Liquidity: Gencurix Inc maintains only 4.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gencurix Inc Industry Peers by Asset Resilience Ratio
Compare Gencurix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Gencurix Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Gencurix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.11% | ₩4.54 Billion | ₩30.04 Billion | -18.54pp |
| 2023-12-31 | 33.65% | ₩11.27 Billion | ₩33.50 Billion | +17.65pp |
| 2022-12-31 | 16.01% | ₩5.96 Billion | ₩37.24 Billion | -23.72pp |
| 2021-12-31 | 39.73% | ₩21.96 Billion | ₩55.29 Billion | +30.93pp |
| 2020-12-31 | 8.80% | ₩5.63 Billion | ₩63.98 Billion | -16.06pp |
| 2019-12-31 | 24.85% | ₩593.34 Million | ₩2.39 Billion | -46.40pp |
| 2018-12-31 | 71.25% | ₩7.23 Billion | ₩10.14 Billion | +9.81pp |
| 2017-12-31 | 61.44% | ₩4.52 Billion | ₩7.36 Billion | -7.41pp |
| 2016-12-31 | 68.85% | ₩6.36 Billion | ₩9.23 Billion | -- |